The latest announcement is out from Achieve Life Sciences Inc (ACHV).
Achieve Life Sciences, Inc. has initiated a Registered Direct Offering and concurrent Private Placement to sell over 13 million shares and warrants, aiming to raise approximately $56.2 million in net proceeds. These funds are earmarked for the clinical development of cytisinicline, including the ORCA-OL clinical trial, and other corporate purposes. The offering is supported by a shelf registration statement and prospectus, with additional potential proceeds of $64.2 million if all Private Placement Warrants are exercised, potentially funding the company’s operations into 2026.
See more data about ACHV stock on TipRanks’ Stock Analysis page.
